GRAL Key Statistics, Chart & Performance
The current stock price of GRAL is 87.88 USD. In the past month the price decreased by -20.39%. In the past year, price increased by 351.83%.
GRAL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About GRAL
Company Profile
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Company Info
GRAIL INC
1525 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 1000
Phone: 18336942553
GRAIL INC / GRAL FAQ
Can you describe the business of GRAIL INC?
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
What is the current price of GRAL stock?
The current stock price of GRAL is 87.88 USD. The price decreased by -4.05% in the last trading session.
Does GRAIL INC pay dividends?
GRAL does not pay a dividend.
What is the ChartMill rating of GRAIL INC stock?
GRAL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is GRAIL INC (GRAL) stock traded?
GRAL stock is listed on the Nasdaq exchange.
How is the valuation of GRAIL INC (GRAL) based on its PE ratio?
GRAIL INC (GRAL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.64).
Can you provide the short interest for GRAL stock?
The outstanding short interest for GRAIL INC (GRAL) is 15.23% of its float.
GRAL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 99.24% of all stocks.
GRAL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GRAL. No worries on liquidiy or solvency for GRAL as it has an excellent financial health rating, but there are worries on the profitability.
GRAL Financial Highlights
Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -11.64. The EPS increased by 90.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.62% | ||
| ROE | -18.14% | ||
| Debt/Equity | 0 |
GRAL Forecast & Estimates
10 analysts have analysed GRAL and the average price target is 107.1 USD. This implies a price increase of 21.87% is expected in the next year compared to the current price of 87.88.
For the next year, analysts expect an EPS growth of 82% and a revenue growth 18.12% for GRAL